Načítá se...
Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib
Ibrutinib is a Bruton tyrosine kinase inhibitor approved for the treatment of patients with relapsed refractory chronic lymphocytic leukemia (RR-CLL). We describe the characteristics, causes of discontinuation, and outcomes in patients who discontinued treatment with ibrutinib. One hundred twenty-se...
Uloženo v:
| Vydáno v: | Blood |
|---|---|
| Hlavní autoři: | , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
American Society of Hematology
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4467871/ https://ncbi.nlm.nih.gov/pubmed/25573991 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-09-603670 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|